Nieuws

BioWorld38 m
In a $1.3B deal, Lilly buys gene editor Verve
With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for ...
BioWorld34 m
Inquis, Penumbra advance thrombectomy treatments
Two med-tech companies focused on pulmonary embolism overcame their own blockages to commercialization this week. Inquis ...